medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2013, Number 3

<< Back Next >>

Neumol Cir Torax 2013; 72 (3)

Impact of both COPD and tabaquism in a cohort of patients with lung cancer

Hernández-Díaz A, Ramos-Quevedo A, Gassiot-Nuño CJ, Cabanes-Varona L, Rodríguez-Vázquez JC, Pablo-Pino P, Lima-Guerra A, Morales-Sánche L

Language: Spanish
References: 80
Page: 197-206
PDF size: 289.90 Kb.


ABSTRACT

Background: Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are illnesses with major mortality in developed countries. They have a high prevalency and mortality which will increase more in the next years. Both diseases share a risk factor, tobacco. Material and methods: A descriptive, retrospective and applied study was conducted. Datas of the medical records were obtained. Smoker or ex-smoker patients with bronchogenic carcinoma in «Hermanos Ameijeiras» Hospital from January 2008 to August 2011 were included. Those whose information was uncompleted were excluded. Results: An important relation between clinical stage of tumoral disease and COPD was founded. More than half of patients was alive at the end of the study. The percentage of patients alives without COPD was almost double of registered in those patients with COPD. Conclusions: Patients with Lung Cancer and COPD predominated. The diagnostic delay was lesser in patients with COPD. Patients with COPD have 4.11 twices more to die that patients whithout it.


REFERENCES

  1. Barreiro E. EPOC y cáncer de pulmón. Arch Bronconeumol 2008;44:399-401.

  2. Miniño AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. National vital statistics reports; 59(2). Hyattsville, MD: National Centre for Health Statistics; 2010. S010.

  3. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 2006;3:535-537.

  4. Clemente GM, Escudero C, Alonso M, et al. Características del carcinoma broncogénico (CB) en pacientes con EPOC. Arch Bronconeumol 2006;42(Supl: Espec Congr):74.

  5. CDC. Cigarette smoking among adults: United States, 2002. MMWR Morb Mortal Wkly Rep 2004;53:427-431.

  6. Murray CJ, López AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.

  7. Sánchez De Cos Escuín J. El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. Arch Bronconeumol 2009;45:341-348.

  8. Peces-Barba G, Barberà JA, Agustí Ầ, et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008;44:271-281.

  9. Instituto Nacional de Estadística. Defunciones según la causa de muerte en España. Madrid: INE; 2008 [citado 5 mayo 2008]. Disponible en: http://www.ine.es

  10. Lence JJ, Camacho R. Cáncer y transición demográfica en América Latina y el Caribe. Rev Cubana Salud Pública [revista en Internet]. 2006 Sep [citado 2008 Ago 10]; 32(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662006000300010&lng=es

  11. Varona PP, Herrera TD, García RGR, Bonet GM, Romero PT, Venero FST. Mortalidad atribuible al tabaquismo en Cuba. Rev Cubana Salud Pública 2009;35:1-13.

  12. Oficina Nacional de Estadísticas. Anuario Estadística 2008. Edición 2009 [sitio en Internet]. 2009 [citado 12 febrero 2010]. Disponible en: http://www.one.cu/aec2008.htm

  13. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C. Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 2005;16:489-511.

  14. Rehm J, Baliunas D, Brochu S, et al. The costs of substance abuse in Canada 2002 [sitio en Internet]. 2006. Fecha de consulta: Marzo 2006. Disponible en: www.ccsa.ca/.../ccsa-011332-2006

  15. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.

  16. Gibbons MA, Sethi T. Chronic obstructive pulmonary disease and lung cancer: inflammation, the missing link. Therapy 2009;6:805-820.

  17. Van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax 2009;64:963-967.

  18. O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-483.

  19. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:258-266.

  20. Masri FA, Comhair SA, Koeck T, et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 2005;172:597-605.

  21. Barreiro E, de la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1116-1124.

  22. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18:222-232.

  23. Turner MC, Chen Y, Krewski D, Calle EE, Thum MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007;176:285-290.

  24. Keith RL, Miller YE, Gemmill RM, et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000;6:1616-1625.

  25. Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):29S-55S.

  26. Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008;14:115-121.

  27. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93:825-833.

  28. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest 2005;128:1895-1897.

  29. Manual de ambientes libres de humo de tabaco. Programa Nacional de Control de Tabaco. Ministerio de Salud y Ambiente de la Nación. [actualizado 2007, citado marzo 2008]. Disponible en: www.msal.gov. ar

  30. Torres DJA, Quesada R, Bayarre VH, et al. Informática médica. Tomo 2. Bioestadística. La Habana: Ciencias Médicas; 2004.

  31. Silva Ayçaguer LC. Muestreo para la investigación en ciencias de la salud. 2da ed. Madrid: Díaz de Santos; 2003.

  32. Nasiff HA, Rodríguez SHM, Moreno RMA. Práctica clínica. La Habana: Ciencias Médicas; 2010.

  33. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123(1 Suppl91):21S-49S.

  34. Estimated new cancer cases and deaths by sex, US, 2009. American Cancer Society [actualizado 2009, citado febrero 2010] Disponible en: http://www.cancer.org/

  35. Freeman HP. Poverty, culture, and social injustice: determinants of cancer disparities. CA Cancer J Clin 2004;54:72-77.

  36. Sánchez de Cos Escuín J, Miravet SL, Abal AJ, et al. Estudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (estudio EpicliCP-2003). Arch Bronconeumol 2006;42:446-452.

  37. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association whit COPD: an analysis using the UK GP Research database. Prim Care Respir J 2010;19:57-61.

  38. Sánchez de Cos Escuín J, Miravet L, et al. Estudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (estudio EpicliCP-2003). Arch Bronconeumol 2006;42:446-452.

  39. Sánchez de Cos Escuín J, Disdier VC, Corral PJ, Riesco MJA, Sojo GMA, Masa JJF. Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados. Arch Bronconeumol 2004;40:268-274.

  40. Estrada TG, Comeche L, López EA, Montoro ZJ, González GF, Colina F. Carcinoma broncogénico 2000-2001: características y supervivencia global. Arch Bronconeumol 2007;43:594-598.

  41. Rodríguez CA, Álvarez VL. Repercusiones del envejecimiento de la población cubana en el sector salud. Rev Cubana Salud Pública [Internet]. 2006 [citado 25 Jul 2011];32(2):178-182. Disponible en: http://scielo.sld.cu/pdf/rcsp/v32n2/spu13206.pdf

  42. Belani CP, Marts S, Schiller J, Socinski MA. Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 2007;55:15-23.

  43. Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004;96:826-834.

  44. Quoix E, Mennecier B. What’s new in the epidemiology of lung cancer: the female aspect? Breathe 2006;2:339-344.

  45. Levi F, Bosetti C, Fernandez E, et al. Trends in lung cancer among young European women: the rising epidemic in France and Spain. Int J Cancer 2007;121:462-465.

  46. Patel J, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004;291:1763-1768.

  47. Gazdar AF, Thun MJ. Lung cancer, smoke exposure, and sex. J Clin Oncol 2007;25:469-471.

  48. González JM, de Castro FJ, Barrueco M, et al. Demoras diagnósticas en el cáncer de pulmón. Arch Bronconeumol 2003;39:437-441.

  49. Hernández-Hernández JR, Heras-Gómez F, Cordovilla-Pérez MR, Antolín-García T, Bollo de ME; Grupo de Estudio CB07-SOCALPAR. Incidencia del carcinoma broncopulmonar en Castilla y León y en Cantabria durante el año 2007. Estudio de la Sociedad Castellano-Leonesa y Cántabra de Patología Respiratoria (SOCALPAR). Arch Bronconemol 2010;46:7-14.

  50. Abal AJ, Blanco RMÁ, Velázquez PM, et al. Cáncer de pulmón en la provincia de Ourense: epidemiología, demoras y supervivencia. Pneuma 2007;8:15-24.

  51. Ramos MM, Esteva CM, Cabeza IE. Demora diagnóstica o terapéutica en cáncer. Portal de oncología. Red IAPP. 2006 [actualizado marzo 2006, citado junio 2009]. Disponible en: http://www.infodoctor.org/sociedades/oncologia_demora.htm

  52. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008;178:738-744.

  53. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007;132:1932-1938.

  54. Strange C. COPD and lung cancer: are they both airways diseases? Chest 2010;138:1289-1290.

  55. Abal AJ, Parente LI, Almazán OR, Blanco PJ, Toubes NME, Marcos VP. Cáncer de pulmón y EPOC: una asociación frecuente. Arch Bronconeumol 2009;45:502-507.

  56. Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):29S-55S.

  57. Imperatori A, Harrison RN, Leitch DN, et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 2006;61:232-239.

  58. Toh CK. The changing epidemiology of lung cancer. Methods Mol Biol 2009;472:397-411.

  59. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24 :2245-2251.

  60. Sánchez de Cos EJ. El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. Arch Bronconeumol 2009;45:341-348.

  61. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008;19:631-640.

  62. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.

  63. Myerson JS, Priest K, Power F, Ashley S, O’Brien MER. Chronic obstructive pulmonary disease in lung cancer underdiagnosed and undertreated. Lung Cancer 2009;63 Suppl 1:S24.

  64. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur J Respir J 2009;34:380-386.

  65. Roca-Ferrer J, Pujols L, Agusti C, et al. La ciclooxigenasa-2 está regulada al alza en el pulmón y en los tumores bronquiales de pacientes con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2011;47:584-589.

  66. Togo S, Holz O, Liu X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med 2008;178:248-260.

  67. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007;30:616-622.

  68. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163:1475-1480.

  69. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005;60:570-575.

  70. Global strategy for the diagnosis, management and prevention of COPD, Global initiative for chronic obstruction lung disease (GOLD) [actualizado febrero 2011, citado mayo 2011]. Disponible en: www.goldcopd.org.

  71. Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med 2008;177:941-946.

  72. Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008;14:115-121.

  73. Sin DD, Anthonisen NR, Soriano JB, Agustí AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-1257.

  74. Baliunas D, Patra J, Rehm J, Popova S, Kaiserman M, Taylor B. Smoking-attributable mortality and expected years of life lost in Canada 2002: conclusions for prevention and policy. Chronic Dis Can 2007;27:154-162.

  75. Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg 2006;81:1830-1838.

  76. Koyi H, Hillerdal G, Brandén E. Patient’s and doctors delays in the diagnosis of chest tumors. Lung Cancer 2002;35:53-57.

  77. Radzikowska E, Glaz P, Roszkowski K. Lung cancer management and prognosis. Pneumonol Alergol Pol 2003;60.

  78. Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Sthále E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax 2004;59:45-49.

  79. Janes S, Spiro S. Are we achieving the current waiting time targets in lung cancer treatment? J Thorac Oncol 2007;2:588-589.

  80. Díez-Herranz A. Enfermedad pulmonar obstructiva crónica y cáncer de pulmón: implicaciones prácticas. Arch Bronconeumol 2001;37:240-247.




2020     |     www.medigraphic.com